Rescue treatment with L-citrulline inhibits hypoxia-induced pulmonary hypertension in newborn pigs

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 2, 2015, Pages 255-264

  Fike, Candice D ^a,b   Dikalova, Anna ^a   Kaplowitz, Mark R ^a   Cunningham, Gary ^c   Summar, Marshall ^c   Aschner, Judy L ^d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Nitric oxide signaling; Superoxide; Uncoupled eNOS

Indexed keywords

CITRULLINE; DIMER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOMER; ARGININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EXPERIMENTAL PIG; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART OUTPUT; HEMODYNAMIC MONITORING; HYPOXIA; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IMMUNOBLOTTING; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; NEWBORN; NONHUMAN; PULMONARY ARTERY; ANIMAL; BLOOD; CELL HYPOXIA; DRUG SCREENING; HYPERTENSION, PULMONARY; METABOLISM; PIG;

ANIMALIA; SUIDAE;

ANIMALS; ANIMALS, NEWBORN; ARGININE; CELL HYPOXIA; CITRULLINE; DRUG EVALUATION, PRECLINICAL; HYPERTENSION, PULMONARY; SUS SCROFA;

EID: 84938920415     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0351OC     Document Type: Article

References (50)

1. Mourani PM, Abman SH. Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 2013; 25:329-337.
2. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005;67:623-661.
3. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002;87: F15-F18.
4. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007;120:1260-1269.
5. Fike CD, Aschner JL, Zhang Y, Kaplowitz MR. Impaired NO signaling in small pulmonary arteries of chronically hypoxic newborn piglets. Am J Physiol Lung Cell Mol Physiol 2004;286:L1244-L1254.
6. Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;188:639-646.
7. Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med 2012;52: 1970-1986.
8. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 2012;302: E481-E495.
9. Fike CD, Dikalova A, Slaughter JC, Kaplowitz MR, Zhang Y, Aschner JL. Reactive oxygen species-reducing strategies improve pulmonary arterial responses to nitric oxide in piglets with chronic hypoxia-induced pulmonary hypertension. Antioxid Redox Signal 2013;18:1727-1738.
10. Gielis JF, Lin JY, Wingler K, Van Schil PE, Schmidt HH, Moens AL. Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders. Free Radic Biol Med 2011;50:765-776.
11. Martásek P, Miller RT, Liu Q, Roman LJ, Salerno JC, Migita CT, Raman CS, Gross SS, Ikeda-Saito M, Masters BSS. The C331A mutant of neuronal nitric-oxide synthase is defective in arginine binding. J Biol Chem 1998;273:34799-34805.
12. Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 1997;96:689-697.
13. Ou Z-J, Wei W, Huang DD, Luo W, Luo D, Wang ZP, Zhang X, Ou JS. L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am J Physiol Endocrinol Metab 2010;298: E1131-E1139.
14. Böger RH. L-arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care 2008;11:55-61.
15. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006;295:58-64.
16. Dikalova A, Fagiana A, Aschner JL, Aschner M, Summar M, Fike CD. Sodium-coupled neutral amino acid transporter 1 (SNAT1) modulates L-citrulline transport and nitric oxide (NO) signaling in piglet pulmonary arterial endothelial cells. PLoS One 2014;9:e85730.
17. Ananthakrishnan M, Barr FE, Summar ML, Smith HA, Kaplowitz M, Cunningham G, Magarik J, Zhang Y, Fike CD. L-citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 2009;297: L506-L511.
18. Fike CD, Kaplowitz MR. Effect of chronic hypoxia on pulmonary vascular pressures in isolated lungs of newborn pigs. J Appl Physiol (1985) 1994;77:2853-2862.
19. Fike CD, Kaplowitz MR. Chronic hypoxia alters nitric oxide-dependent pulmonary vascular responses in lungs of newborn pigs. J Appl Physiol (1985) 1996;81:2078-2087.
20. Fike CD, Dikalova A, Kaplowitz M, Summar M, Aschner J. L-citrulline recouples eNOS and ameliorates progressive chronic hypoxia-induced pulmonary hypertension in newborn pigs. EPAS 2014: 4535.5.
21. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 2010;107: 106-116.
22. Dikalova A, Clempus R, Lassègue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-2676.
23. Fike CD, Sidoryk-Wegrzynowicz M, Aschner M, Summar M, Prince LS, Cunningham G, Kaplowitz M, Zhang Y, Aschner JL. Prolonged hypoxia augments L-citrulline transport by system A in the newborn piglet pulmonary circulation. Cardiovasc Res 2012;95:375-384.
24. Meier U. A note on the power of Fisher's least significant difference procedure. Pharm Stat 2006;5:253-263.
25. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138: 682-692.
26. Tonelli AR, Haserodt S, Aytekin M, Dweik RA. Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy. Pulm Circ 2013;3:20-30.
27. Böger RH, Mügge A, Bode-Böger SM, Heinzel D, Höper MM, Frölich JC. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 1996;34: 323-328.
28. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991;338:1546-1550.
29. Schulze-Neick I, Penny DJ, Rigby ML, Morgan C, Kelleher A, Collins P, Li J, Bush A, Shinebourne EA, Redington AN. L-arginine and substance P reverse the endothelial dysfunction caused by congenital heart surgery. Circulation 1999;100:749-755.
30. Neill MA, Aschner J, Barr F, Summar ML. Quantitative RT-PCR comparison of the urea and nitric oxide cycle gene transcripts in adult human tissues. Mol Genet Metab 2009;97:121-127.
31. Vadivel A, Aschner JL, Rey-Parra GJ, Magarik J, Zeng H, Summar M, Eaton F, Thébaud B. L-citrulline attenuates arrested alveolar growth and pulmonary hypertension in oxygen-induced lung injury in newborn rats. Pediatr Res 2010;68:519-525.
32. Smith HAB, Canter JA, Christian KG, Drinkwater DC, Scholl FG, Christman BW, Rice GD, Barr FE, Summar ML. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg 2006;132:58-65.
33. Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HAB, Campbell A, Canter JA, Christian KG, et al. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg 2007;134:319-326.
34. Flam BR, Hartmann PJ, Harrell-Booth M, Solomonson LP, Eichler DC. Caveolar localization of arginine regeneration enzymes, argininosuccinate synthase, and lyase, with endothelial nitric oxide synthase. Nitric Oxide 2001;5:187-197.
35. Fike CD, Pfister SL, Kaplowitz MR, Madden JA. Cyclooxygenase contracting factors and altered pulmonary vascular responses in chronically hypoxic newborn pigs. J Appl Physiol (1985) 2002;92:67-74.
36. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
37. Konduri GG, Bakhutashvili I, Eis A, Pritchard K Jr. Oxidant stress from uncoupled nitric oxide synthase impairs vasodilation in fetal lambs with persistent pulmonary hypertension. Am J Physiol Heart Circ Physiol 2007;292:H1812-H1820.
38. Steinhorn RH, Albert G, Swartz DD, Russell JA, Levine CR, Davis JM. Recombinant human superoxide dismutase enhances the effect of inhaled nitric oxide in persistent pulmonary hypertension. Am J Respir Crit Care Med 2001;164:834-839.
39. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999;103:610-618.
40. Lönnqvist PA, Jonsson B, Winberg P, Frostell CG. Inhaled nitric oxide in infants with developing or established chronic lung disease. Acta Paediatr 1995;84:1188-1192.
41. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman RW, Berkelhamer SK, Steinhorn RH, et al. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1a. Am J Respir Crit Care Med 2014;189:314-324.
42. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-1960.
43. Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake by the splanchnic region in adult humans. Am J Physiol 1993;265:E532-E539.
44. Wu G. Intestinal mucosal amino acid catabolism. J Nutr 1998;128: 1249-1252.
45. Curis E, Nicolis I, Moinard C, Osowska S, Zerrouk N, Bénazeth S, Cynober L. Almost all about citrulline in mammals. Amino Acids 2005;29:177-205.
46. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr 2002;22:87-105.
47. Rougé C, Des Robert C, Robins A, Le Bacquer O, Volteau C, De La Cochetière MF, Darmaun D. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol 2007;293: G1061-G1067.
48. Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, Schulze F, Böger RH. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008;65: 51-59.
49. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007;116:188-195.
50. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee H-S, et al.; Urea Cycle Disorders Consortium of the Rare Diseases Clinical Research Network. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008;94:397-402.